KalVista Pharmaceuticals, Inc. (KALV)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$125.0M
Cash & Equivalents
$14.5M
Quarterly Burn Rate
26 mo
Est. Cash Runway
$1,438M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
SEBETRALSTAT
EKTERLY 		APPROVED Angioedema, Hereditary, Types I and II, Diabetic Macular Edema, Hereditary Angioedema

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for KALV.

SEC EDGAR Filings

All SEC filings for KalVista Pharmaceuticals, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.